Sunobinop Scientific Publications

A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Interactions Between Alcohol and Sunobinop in Healthy Participants.

J Clin Psychopharmacol. 2026;April 3.

Harris S, Shet M, Cipriano A, et al.

Human Abuse Potential of Single Oral Doses of Sunobinop, a Novel, Highly Potent, and Selective Partial Agonist for Nociceptin/Orphanin-FQ Peptide (NOP) Receptors.

J Clin Psychopharmacol.2026;46(3):297-310.

Harris SC, Cipriano A, Whiteside GT, et al.

In Vitro Pharmacological Evaluation of the Novel NOP Receptor Partial Agonist Sunobinop.

Biochem Pharmacol. 2025;238:116972.

Camilotto R, Malfacini D, Pola P, et al.

Evaluation of Sunobinop for Next-Day Residual Effects in Healthy Participants.

Front Pharmacol. 2024;15:1432902.

Cipriano A, Kapil RP, Zhou M, et al.

Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-Ascending Doses of Sunobinop in Healthy Participants.

Clin Pharmacol Drug Dev. 2024;13(7):790-800.

Cipriano A, Kapil RP, Zhou M, et al.

Efficacy and Safety of a Selective Partial Agonist for Nociception/Orphanin-FQ Peptide (NOP) Receptors in Patients With Insomnia Disorder.

Br J Clin Pharmacol. 2026;92(1):172-185.

Whiteside GT, He E, Shet M, Zhou M, Ahmad M, Harris SC.

The Nociceptin/Orphanin FQ Receptor Partial Agonist Sunobinop Promotes Non-REM Sleep in Rodents and Patients with Insomnia.

J Clin Invest. 2024;134(1):e171172.

Whiteside GT, Kyle DJ, Kapil RP, et al.

Results from a Phase 2, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group Study of Sunobinop in Subjects Who Are Experiencing Insomnia During Recovery from Alcohol Use Disorder.

Drug and Alcohol Dependence. 2024;260(S):110455.

Sessler N, Harris SC, Zhou M, et al.

Safety, Tolerability, and Efficacy of a Novel, Highly Potent and Selective Partial Agonist for Nociceptin/Orphanin-FQ Peptide (NOP) Receptors in Patients with Insomnia Disorder.

Sleep. 2020;43(S1):A192.

Zhou M, Harris SC, Kapil RP, et al.

Evaluation of the Human Abuse Potential of Single Oral Doses of V117957, a Novel, Highly Potent and Selective Partial Agonist for Nociceptin/Orphanin-FQ Peptide (NOP) Receptors.

Sleep. 2020;43(S1):A191-A192.

Harris SC, Zhou M, Cipriano A, et al.

Activation of Nociceptin/Orphanin-FQ Peptide (NOP) Receptors Produces an Increase in Non-REM Sleep in Rats and Constitutes a Novel and Attractive Target for the Treatment of Insomnia.

Sleep. 2020;43(S1):A1.

Whiteside GT, Hummel M, Knappenberger T, et al.

Medical Claims Data Analysis of Comorbidities in Patients with Interstitial Cystitis / Bladder Pain Syndrome.

Continence. 2024;7(S1):100823.

Pascale V, Yu T, Onyekwere U, Zhao X, Wang S, Mikl J.

Effects of Sunobinop (V117957) in a Model of Acute Cystitis Induced by Cyclophosphamide.

The Journal of Urology. 2023;209(S4):E152.

Whiteside GT, Auge, C, Lluel P.

Pharmacologic Treatment of Insomnia Reduces Risk of Return to Alcohol Use in Patients in Recovery From Alcohol Use Disorder.

J Stud Alcohol Drugs. 2026;87(2):314–322.

Mikl J, Yu T, Singh S, et al.

Current and Potential Pharmacological Treatment Options for Insomnia in Patients with Alcohol Use Disorder in Recovery.

Neuropsychopharmacol Rep. 2020;40(3):211-223.

Roehrs TA, Auciello J, Tseng J, Whiteside G.

Psychomotor/Cognitive Effects, Pharmacokinetics and Safety of V117957, a Novel, Highly Potent and Selective Partial Agonist for Nociceptin/Orphanin-FQ Peptide (NOP) Receptors, Administered in Combination with Alcohol in Healthy Subjects.

Sleep. 2020;43(S1):A78.

Zhou M, Harris, SC, Cipriano, A, et al.